Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | CPS1 | P31327 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665656 | 0.77 | NAAA (0.40) | — | |
| SCHEMBL4290435 | 0.76 | SMN1; SMN2 (0.48) | CHRNA3ALDH1A1ATMCPS1 | |
| SCHEMBL22322036 | 0.74 | ALDH1A1 (0.57) | ALDH1A1ATM | |
| SCHEMBL4290438 | 0.72 | SMN1; SMN2 (0.43) | ALDH1A1ATMCPS1 | |
| SCHEMBL1665636 | 0.71 | SMN1; SMN2 (0.60) | ALDH1A1 | |
| SCHEMBL13662434 | 0.71 | GPR119 (0.45) | ALDH1A1 | |
| SCHEMBL1667625 | 0.70 | KMT2A (0.48) | ALDH1A1TRIM24TYRTRIM33ERN1 | |
| SCHEMBL14451166 | 0.68 | THRB (0.41) | ALDH1A1TRIM24TYRTRIM33ERN1 | |
| SCHEMBL14285929 | 0.68 | ALDH1A3 (0.52) | ALDH1A1TRIM24TYRTRIM33ERN1 | |
| SCHEMBL1665980 | 0.67 | ALDH1A1 (0.38) | ALDH1A1TRIM24TYRTRIM33ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493905-B1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | WARNER CHILCOTT CO LLC (PR) | 2016-11-30 | — | — | EP | disclosed |
| US-8822435-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140194389-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-8710215-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130035482-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2013-02-07 | — | — | US | disclosed |
| US-8314081-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2493905-A1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | Warner Chilcott Company, LLC (PR) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011056589-A1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | WARNER CHILCOTT COMPANY, LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110098251-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194389-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | CHRNA3 4712/4885ALDH1A1 2404/4885TRIM24 4622/4885 |
| US-20110098251-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | CHRNA3 4712/4885ALDH1A1 2404/4885TRIM24 4622/4885 |
| US-20130035482-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | CHRNA3 4712/4885ALDH1A1 2404/4885TRIM24 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.